文献速递心脏核医学神经核医学肿瘤 PET/CT

FLT-PET评估系统性结节病(含心脏及中枢神经系统受累)的前瞻性研究:与FDG-PET对比

FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET.
PubMed 文献 · EJNMMI Res · 2020-12-10

FLT-PET在12例(86%)阳性、FDG-PET在11例(79%)阳性;FLT与FDG在结节病、肺部受累、心脏结节病及神经结节病诊断上具有良好至优秀的一致性。FLT-PET或可用于系统性结节病及心脏、神经受累的评估。

要点

  • FLT-PET无需心脏抑制准备且脑本底低,或可弥补FDG-PET评估心脏和神经结节病的不足。
  • FLT与FDG诊断一致性良好至优秀(κ=0.69~1.0),FLT观察者间一致性优秀。
  • 校正血池活性后FLT与FDG的SUV无显著差异(p=0.90)。

核心结论

  • FLT-PET可能可用于系统性结节病以及心脏和神经受累的评估。

研究设计与样本

  • 采用Cohen kappa和组内相关系数评估FLT与FDG-PET的一致性,并评估FLT与FDG-PET的观察者间变异。

主要发现

  • 12例符合心脏结节病(CS)的Heart Rhythm Society标准,1例有神经结节病(NS)。
  • FLT-PET阳性12例(86%),FDG-PET阳性11例(79%);CS患者中FLT心脏摄取6例(50%),FDG心脏摄取7例(58%)。
  • 1例NS患者在FLT与FDG-PET上均显示摄取,FLT上病灶更多。
  • FLT与FDG病灶解剖分布无显著差异;FDG的SUV显著高于FLT(5.8±3.0 vs 2.3±1.1,p<0.001),但校正血池活性后无显著差异(2.8±1.4 vs 2.8±1.1,p=0.90)。
  • FLT与FDG-PET在结节病、肺部受累、CS和NS诊断上的一致性良好至优秀(κ分别为0.76、0.69、0.86、1.0);FLT观察者间一致性在结节病、CS和NS诊断上优秀(κ分别为0.81、0.85、1.0),与FDG相当。

关键数值与推荐

  • CS诊断依据Heart Rhythm Society标准。
  • FLT与FDG-PET一致性κ值:结节病0.76、肺部受累0.69、CS 0.86、NS 1.0。
  • FLT观察者间一致性κ值:结节病0.81、CS 0.85、NS 1.0。

临床怎么用

  • 对需评估心脏或神经结节病且不便进行心脏抑制准备的患者,可考虑FLT-PET作为FDG-PET的替代或补充。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 2-deoxy-2-[18F]fluoro-D-glucose's (FDG) biodistribution limits the evaluation of cardiac sarcoidosis (CS) and neurosarcoidosis (NS). While protocols for cardiac suppression exist, they can be inconvenient for patients and lead to incomplete cardiac suppression in many cases. Furthermore, FDG PET is limited in the detection of neurosarcoidosis due to an inability to suppress high level of physiological uptake within the brain. 3'-deoxy-3'-[18F]fluorothymidine (FLT) has been shown to accumulate in sarcoidosis lesions and this tracer lacks significant physiological myocardial and brain uptake, suggesting that this tracer may be useful for the assessment of sarcoidosis, including CS and NS, without the need for patient preparation. This prospective pilot study examined the performance of FLT vs FDG PET for systemic sarcoidosis, including cardiac and neural involvement. MATERIALS AND METHODS: Fourteen subjects with sarcoidosis were prospectively recruited and imaged with FDG- and FLT-PET. Two blinded, experienced readers independently reviewed the FLT-PET and FDG-PET images. Lesion distribution was compared between FLT and FDG. Agreement between FLT- and FDG-PET was determined using Cohen's kappa and the intra-class correlation coefficient. Inter-observer variability of FLT and FDG-PET was assessed. RESULTS: Twelve subjects had CS as per Heart Rhythm Society criteria and 1 had NS. FLT-PET was positive in 12 (86%), and FDG-PET in 11 (79%), with cardiac uptake present in 6 (50%) and 7 (58%) of subjects with CS, respectively. The subject with NS demonstrated uptake on both FLT and FDG-PET, with more lesions on FLT. There were no significant differences in the anatomical distribution of lesions between FLT and FDG. SUVs were significantly (p < 0.001) higher for FDG than FLT (5.8 ± 3.0 vs 2.3 ± 1.1, respectively), but not (p = 0.90) after adjusting for blood pool activity (2.8 ± 1.4 vs 2.8 ± 1.1, respectively). Agreement between FLT- and FDG-PET was good to excellent for the diagnosis of sarcoidosis, lung involvement, CS, and NS (κ = 0.76, 0.69, 0.86, and 1.0, respectively). Inter-observer agreement for FLT was excellent for diagnosing sarcoidosis, CS and NS (κ = 0.81, 0.85, and 1.0, respectively) and comparable to that of FDG. CONCLUSIONS: FLT-PET may be useful for the assessment of systemic sarcoidosis, as well as cardiac and neural involvement.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Martineau P, Pelletier-Galarneau M, Juneau D, et al. FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET. EJNMMI Res. 2020. PMID: 33301054. doi:10.1186/s13550-020-00742-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。